Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Feb:32:55-58.
doi: 10.1016/j.jdcr.2021.12.002. Epub 2022 Jan 7.

Erythema multiforme reactions after Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccination: A case series

Elif Karatas  1 , Ali Nazim  2 , Parth Patel  3 , Toral Vaidya  4 , George Scott Drew  5 , Sanober A Amin  6 , Ashley A Keyes  4 , Maira Fonseca  4 , Adnan Mir  7 , Caroline P Halverstam  3
Affiliations
Case Reports

Erythema multiforme reactions after Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccination: A case series

Elif Karatas et al. JAAD Case Rep. 2023 Feb.
No abstract available

Keywords: COVID-19 vaccination; EM, erythema multiforme; HSV, herpes simplex virus; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; cutaneous adverse events; erythema multiforme.

PubMed Disclaimer

Conflict of interest statement

None disclosed.

Figures

Fig 1
Fig 1
Well-demarcated, edematous targetoid papules and plaques around the knee.
Fig 2
Fig 2
Punch biopsy specimen from the trunk showing vacuolar interface changes with occasional eosinophils. (Hematoxylin-eosin stain; original magnification: ×20.)
Fig 3
Fig 3
Erythematous targetoid plaques on the hand.
Fig 4
Fig 4
Erythematous targetoid plaques on the trunk.
Fig 5
Fig 5
Erythematous targetoid plaques on the dorsum of the bilateral hands.
See this image and copyright information in PMC

References

    1. Baden L.R., El Sahly H.M., Essink B., et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. doi: 10.1056/NEJMoa2035389. - DOI - PMC - PubMed
    1. Polack F.P., Thomas S.J., Kitchin N., et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed
    1. McMahon D.E., Amerson E., Rosenbach M., et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46–55. doi: 10.1016/j.jaad.2021.03.092. - DOI - PMC - PubMed
    1. Rosenblatt A.E., Stein S.L. Cutaneous reactions to vaccinations. Clin Dermatol. 2015;33(3):327–332. doi: 10.1016/j.clindermatol.2014.12.009. - DOI - PubMed
    1. French L.E., Prins C. In: 2nd ed. Bolognia J.L., Jorizzo J.L., Rapini R.P., editors. vol 1. Mosby Elsevier; 2008. Erythema multiforme, Stevens–Johnson syndrome and toxic epidermal necrolysis; pp. 287–300. (Dermatology).

Publication types